NVO vs. QGEN: Novo Nordisk vs. Qiagen Stock Comparison

Company Profile

Novo Nordisk (NVO) and Qiagen (QGEN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but NVO is classified in Pharmaceuticals while QGEN is classified in Life Sciences Tools & Services.

Qiagen (QGEN) trades as ordinary local shares, while Novo Nordisk (NVO) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Novo Nordisk (NVO) at 58.38% and Qiagen (QGEN) at 10.81% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Novo Nordisk (NVO) at 33.92% and Qiagen (QGEN) at 18.20% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Novo Nordisk (NVO) at 40.05% and Qiagen (QGEN) at 27.75% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Novo Nordisk (NVO) at 6.43% and Qiagen (QGEN) at 5.65% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Qiagen (QGEN) at 409.76% clears its industry range for EPS growth, a much stronger earnings trajectory than Novo Nordisk (NVO) at 1.77%, which is closer to a typical peer reading.

Growth Metrics

Financial Strength

Qiagen (QGEN) at 2.63 keeps current ratio within its industry’s typical mid-range, while Novo Nordisk (NVO) at 0.85 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for NVO.

Both Novo Nordisk (NVO) at 0.62 and Qiagen (QGEN) at 0.47 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Both Novo Nordisk (NVO) at 29.03% and Qiagen (QGEN) at 0.71% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Novo Nordisk (NVO) at 45.36% and Qiagen (QGEN) at 18.21% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

Novo Nordisk (NVO) at 10.18 sits in the cheaper P/E ratio quartile, while Qiagen (QGEN) at 27.21 is closer to its industry’s usual earnings multiple — a discount for NVO, though growth and earnings durability still matter.

Novo Nordisk (NVO) at 0.53 sits in the cheaper P/S ratio quartile while Qiagen (QGEN) at 4.91 prices around its industry’s middle — NVO costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Novo Nordisk (NVO) at 5.43 and Qiagen (QGEN) at 2.99 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics